Showing results (201-210 of 277) with videos related to

Sort By:
Pageof 28
Nature Communications|March 26, 2024
Phenome-wide Mendelian randomisation analysis of 378,142 cases reveals risk factors for eight common cancersMolly Went, Amit Sud, Charlie Mills, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 22, 2021
Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four TrialSarah Brown, Charlotte Pawlyn, Avie-Lee Tillotson, et al.
Medrxiv : the Preprint Server for Health Sciences|April 17, 2023
Risk factors for eight common cancers revealed from a phenome-wide Mendelian randomisation analysis of 378,142 cases and 485,715 controlsMolly Went, Amit Sud, Charlie Mills, et al.
European Journal of Haematology|March 12, 2008
Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myelomaMartin Kaiser, Maren Mieth, Peter Liebisch, et al.
Blood Cancer Journal|October 15, 2020
An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamicsPhuc H Hoang, Alex J Cornish, Amy L Sherborne, et al.
Ejhaem|June 18, 2025
Risk adapted therapy for newly diagnosed multiple myeloma delivered through local cytogenetic laboratories in a National Clinical Trial: UKMRA RADAR studyDipal Mehta, Robert Cicero, Laura Chiecchio, et al.
Cell Reports. Medicine|February 28, 2024
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trialJames Larkin, Richard Marais, Nuria Porta, et al.
Angewandte Chemie (International Ed. in English)|May 3, 2021
Tricyanidoferrates(-IV) and Ruthenates(-IV) with Non-Innocent Cyanido LigandsFranziska Jach, Frank R Wagner, Zeeshan H Amber, et al.
Leukemia|October 16, 2019
The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trialCharlotte Pawlyn, David Cairns, Martin Kaiser, et al.
BMC Hematology|May 19, 2016
The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myelomaSarah Brown, Samantha Hinsley, Mónica Ballesteros, et al.
Pageof 28